Alejandro Vasquez, MD
Interventional Cardiology · Huntsville, ALNPI 1164493367
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 76.0% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $16,769 and has fallen 67.8% since, to $5,394 in 2025.
Across 488 payments — averaging $91.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$34K
- Boston Scientific$4K
- Abbott$2K
- Medtronic$1K
- Novartis$750
- Pfizer$686
- plus $3K from 24 others
Across 148 payments — averaging $7730.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$501K
- Boehringer Ingelheim Pharma GmbH & Co.kg$232K
- CSL Behring$225K
- Boehringer Ingelheim International GmbH$177K
- Boston Scientific$9K
What the payments were for
- Consulting fees$16,95938%
- Speaking & faculty fees$1,5003%
- Travel & lodging$11,96727%
- Food & beverage$14,42332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 121 | $34,105 |
| Boston Scientific | 61 | $3,532 |
| Abbott | 45 | $2,016 |
| Medtronic(2 entities) | 40 | $1,010 |
| Novartis | 44 | $750 |
| Pfizer | 31 | $686 |
| Johnson & Johnson | 31 | $468 |
| Amgen | 24 | $380 |
| E.r. Squibb & Sons, L.L.C. | 11 | $352 |
| AstraZeneca | 13 | $306 |
| Novo Nordisk | 14 | $236 |
| Boehringer Ingelheim | 6 | $127 |
| Regeneron Healthcare Solutions, Inc. | 7 | $124 |
| Sanofi-aventis U.S. LLC | 8 | $122 |
| Shockwave Medical, Inc | 1 | $109 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $101 |
| Abiomed | 3 | $81 |
| Cardiovascular Systems Inc. | 8 | $79 |
| Bayer | 3 | $71 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Merck | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Recor Medical Inc | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Gilead | 1 | $14 |
| Atricure, Inc. | 1 | $13 |
| Philips North America LLC | 1 | $12 |
| Chiesi USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$24,385
- Watchman$2,564
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$2,540
- NAVITOR$430
- Optis Coronary Imaging System$387
- CoreValve Evolut$196
- COREVALVE EVOLUT R$148
- AVVIGO Guidance System$146
- SAPIEN 3 Ultra RESILIA$138
- WATCHMAN Access System$129
- CARDIOMEMS$127
- FARXIGA$125
- MitraClip System$124
- OPTIS$114
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$109
How this compares
$44,850 in reported general payments places this provider in the 85th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 381 | $394,401 |
| EntrestoSacubitril/Valsartan | 276 | $293,908 |
| Repatha SureclickEvolocumab | 73 | $66,127 |
| XareltoRivaroxaban | 72 | $64,172 |
| JardianceEmpagliflozin | 42 | $41,947 |
| Praluent PenAlirocumab | 30 | $20,971 |
| FarxigaDapagliflozin Propanediol | 23 | $16,743 |
| Ranolazine ErRanolazine | 75 | $11,485 |
| BrilintaTicagrelor | 16 | $7,188 |
| Prasugrel Hcl | 81 | $5,199 |
| Rosuvastatin Calcium | 208 | $4,955 |
| Amiodarone Hcl | 91 | $4,842 |
| Metoprolol Succinate | 242 | $4,834 |
| Atorvastatin Calcium | 309 | $3,818 |
| ClopidogrelClopidogrel Bisulfate | 291 | $3,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $686 | $394,401381 claims |
| NovartisEntresto | $750 | $293,908276 claims |
| Johnson & JohnsonXarelto | $468 | $64,17272 claims |
| Boehringer IngelheimJardiance | $127 | $41,94742 claims |
| AstraZenecaFarxiga, Brilinta | $306 | $23,93039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Huntsville
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- David DrenningHuntsville$31K
- Clarence GillHuntsville$13K
- Victor OkunrintemiHuntsville$12K
- Henry ChenHuntsville$8K
- Mihir KanitkarHuntsville$7K
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.